Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial

Robert E Mansel, Lesley Fallowfield, Mark Kissin, Amit Goyal, Robert G Newcombe, J Michael Dixon, Constantinos Yiangou, Kieran Horgan, Nigel Bundred, Ian Monypenny, David England, Mark Sibbering, Tholkifl I Abdullah, Lester Barr, Utheshtra Chetty, Dudley H Sinnett, Anne Fleissig, Dayalan Clarke, Peter J Ell

Research output: Contribution to journalArticlepeer-review

Abstract

Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes. We conducted a multicenter randomized trial to compare quality-of-life outcomes between patients with clinically node-negative invasive breast cancer who received sentinel lymph node biopsy and patients who received standard axillary treatment.
Original languageEnglish
Pages (from-to)599-609
Number of pages11
JournalJNCI: Journal of the National Cancer Institute
Volume98
Issue number9
DOIs
Publication statusPublished - 3 May 2006

Keywords

  • Arm
  • Axilla
  • Breast Neoplasms
  • Breast Neoplasms, Male
  • Carcinoma, Ductal, Breast
  • Carcinoma, Lobular
  • Drainage
  • Female
  • Humans
  • Incidence
  • Length of Stay
  • Lymph Node Excision
  • Lymphatic Metastasis
  • Lymphedema
  • Male
  • Mastectomy
  • Middle Aged
  • Movement
  • Quality of Life
  • Radiotherapy, Adjuvant
  • Risk Assessment
  • Sentinel Lymph Node Biopsy
  • Shoulder
  • Surgical Wound Infection
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial'. Together they form a unique fingerprint.

Cite this